Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor which is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins for NRAS-mutated solid tumors; RLY-1013, an oral, potent, selective, bifunctional protein degrader of estrogen receptor alpha; RLY-2139, an oral, small molecule, potent, and selective inhibitor of Cyclin-dependent kinases (CDK2) that spares other CDKs. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. Further, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer for the development of RLY-2608. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics Inc.

Relay Therapeutics received a Buy rating and a price target from Wells Fargo analyst Eva Fortea Verdejo today. According to TipRanks, Fortea Verdej...

Positive Report for Relay Therapeutics (RLAY) from Wells Fargo

Barclays analyst Etzer Darout maintained a Buy rating on Relay Therapeutics today and set a price target of $17.00. Darout covers the Healthcare se...

Market Cap	$1.07B	P/E Ratio	N/A
52W High	$8.70	52W Low	$1.78
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	14.8%	52W Position	90.3%
Overall Score	55	Value Score	60
Quality Score	44	Technical Score	63

EPS Current Est	$-1.68	EPS Next Est	$-1.59
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLAY	$8.03	+3.08%	2.84M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLAY	$8.03	+3.1%	2.84M
3
4
5
6

RLAY

RLAY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Relay Therapeutics Inc. Data in Excel

Get Relay Therapeutics Inc. Data in Excel